Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase 0
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 09 Mar 2017 Status changed from discontinued to withdrawn prior to enrolment.
- 20 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Oct 2009 New trial record